These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 7701577)

  • 1. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
    Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Kidney-pancreas transplantation. Clinical results in 23 consecutive patients].
    Maestri M; Krieger N; Kuo P; Dafoe DC; Alfrey EJ
    Minerva Chir; 1998 Mar; 53(3):121-8. PubMed ID: 9617106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Low-dose antithymocyte globulins in kidney transplantation: results of a protocol of intermittent administration].
    Mourad G; Portales P; Garrigue V; Djamali A; Bouloux C; Chong G; Clot J
    Nephrologie; 2000; 21(5):253-8. PubMed ID: 11068775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients.
    Schnetzler B; Leger P; Völp A; Dorent R; Pavie A; Gandjbakhch I
    Transpl Int; 2002 Jun; 15(6):317-25. PubMed ID: 12072903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin.
    Zhang R; Haverich A; Strüber M; Simon A; Bara C
    J Heart Lung Transplant; 2008 Jun; 27(6):603-9. PubMed ID: 18503958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.
    Abouna GM; al-Abdullah IH; Kelly-Sullivan D; Kumar MS; Loose J; Phillips K; Yost S; Seirka D
    Transplantation; 1995 Jun; 59(11):1564-8. PubMed ID: 7778170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
    Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
    Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation.
    Aleksic I; Freimark D; Blanche C; Czer LS; Dalichau H; Valenza M; Takkenberg JJ; Trento A
    Thorac Cardiovasc Surg; 1997 Aug; 45(4):190-5. PubMed ID: 9323821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
    J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA; Khawand N; Aquino A; Ali A; Korb S
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
    Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B
    J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.